Spotlight
Video

ASCO 2017- Safety and efficacy of daratumumab-based regimens in elderly patients with RRMM

Loading........
Description: Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR

Background: Daratumumab (D) plus lenalidomide and dexamethasone (Rd; POLLUX) or with bortezomib and dexamethasone (Vd; CASTOR) demonstrated prolonged PFS and tolerability compared with Rd and Vd alone, respectively, in RRMM pts. We examined the safety and efficacy profiles of DRd and DVd in elderly (≥75 y) pts from these phase 3 studies.
Shared By : InternationalMyelomaFoundation
Posted on : 08/15/17
Added : 3 months ago
Category : Multiple Myeloma



Recommended

Nothing found.